Global Female Infertility Diagnosis and Treatment Market 2022-2028

Global Female Infertility Diagnosis and Treatment Market 2022-2028

The global female infertility diagnosis and treatment market is anticipated to grow at a significant CAGR of 5.6% during the forecast period (2022-2028). Increasing infertility and changing lifestyles drive the growth of the global female infertility diagnosis and treatment market. For instance, according to the center for disease control and prevention in December 2021, in the US, around 13.8% of women aged 15-49 have impaired fecundity, and 26% of married women of the same age group are suffered from impaired fecundity. This, in turn, is expected to propel the demand for female infertility diagnosis and treatment. Furthermore, the rising trends of surrogacy, the growing infertility rate among females, and new technologies to avoid multiple embryo implants are estimated to be the major factors that are contributing to the growth of the market.

However, certain factors restrained the growth of the market, such as the high cost of infertility treatment, and the low accuracy rate of the treatment. Moreover, the social stigma related to infertility treatment is another factor that may hinder the global female infertility diagnosis and treatment market across the globe.

Impact of COVID-19 Pandemic on Global Female Infertility Diagnosis and Treatment Market

The COVID-19 pandemic has had adverse effects on the market. The global fertility rates have been in decline for years, and the COVID-19 pandemic has amplified this trend, particularly for women. A report published by, the National Bureau of Economic Research in February 2022, shows that many US women planned to delay or avoid childbearing as the economy slowed during the COVID-19 pandemic, and access to contraception and abortion fell, as reproductive health centers across the world temporarily closed or reduced their capacity. Moreover, according to the 2020 Guttmacher Survey of Reproductive Health, 33 percent of women had to delay or cancel visiting their health care provider or had trouble getting their birth control due to the pandemic

Segmental Outlook

The global female infertility diagnosis and treatment market is segmented on the basis of diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into the ovulation testing, ovarian reserve testing, hormonal level testing, hysterosalpingography (HSG), hysteroscopy, imaging testing, genetic testing, and others. The ovulation testing segment is anticipated to show a significant growth rate in the market, owing to technological advancements in ovulation test kits to get accurate and reliable results. Based on treatment, the market is fragmented into drugs, surgery, IUI, and ART. The market is further analyzed based on end-users of the female infertility diagnosis and treatment, including hospitals and clinics, homecare, and pathology and diagnostic centers.

Assisted Reproductive Technology (ART) is estimated to propel at a considerable growth rate in the market

Among the type of treatments, the ART segment is projected to witness a considerable growth rate during the forecast period. The growth is driven by the factors such as the newly invented techniques that are used to treat a condition which include, in-vitro fertilization(IVF), artificial insemination(AI-IUI), and frozen embryo transfer(FET), and gamete intrafallopian transfer(GIFT). Furthermore, a rise in the funding from private and government organizations for infertility services, and an increased awareness regarding infertility treatment and surrogacy, drive the growth of the segment in the global female infertility diagnosis and treatment market.

Regional Outlooks

The global female infertility diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). North America is anticipated to hold a significant share in the global market. The declining fertility rates, the rising median age of first-time pregnancy, and the increase in healthcare expenditure are the major factors that are contributing to the market growth in North America. Moreover, the presence of major market players in this region, including Pfizer Inc. North America, followed by Europe are expected to boost the global female infertility diagnosis and treatment market during the forecast period.

Asia-Pacific expected to propel with Significant Growth in the Global Female Infertility Diagnosis and Treatment Market

Asia-Pacific is estimated to project a significant growth rate in the global market. The declining birth rate in some major countries of Asia-Pacific, such as Japan, Singapore, Taiwan, and South Korea is a major factor to drive the growth of the female infertility diagnosis and treatment market in the region. The government of countries such as South Korea and Singapore is offering IVF treatment at subsidized rates to improve the birth rate in the countries. New product developments launched by market players are further aid in market growth. For instance, in April 2022, Israel-based Embryonics announced its first collaboration in India with the Jaslok-FertileTree International fertility center. The newly set up partnership will aim to help increase the success rate of fertility treatment in the Indian subcontinent. Embryonic uses tens of thousands of data points from large clinics in the US, Isreal, Europe, and Asia-Pacific, and the first product to reach the market is UBER, CE. UBER, is equipped with cloud-based software that uses tie lapse videos or single images of blastocysts to predict implantation probability, automatically annotate morphokinetic events, and assist embryo selection using a data-driven approach.

Market Players Outlook

The prominent players contributing globally in the female infertility diagnosis and treatment market are Bayer AG, Church & Dwight Co. Inc., Genea Ltd., Pfizer Inc., Vitrolife Sweden AB, Esco Group, Fairhaven Health, Ferring B.V., and others. These key manufacturers are adopting various strategies like new product launches, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance,in January 2022, Eggschain announced a partnership with the Boston IVF chain of 30 fertility clinics in the US. With this partnership, the eggs chain aids in the tracking of cryogenically preserved sperm which is to be used for in vitro fertilization(IVF) through blockchain technology provided by the eggs chain.

The Report Covers

Market value data analysis of 2021 and forecast to 2028.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global female infertility diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.